menu
    • menu
    [{"orgOrder":0,"company":"OncoQuest","sponsor":"Dual Industrial","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2020","type":"Divestment","leadProduct":"Carboplatin","moa":"||Mucin-16","graph1":"Oncology","graph2":"Phase III","graph3":"OncoQuest","amount2":0.38,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.38,"dosageForm":"Infusion","sponsorNew":"OncoQuest \/ Dual Industrial","highestDevelopmentStatusID":"10","companyTruncated":"OncoQuest \/ Dual Industrial"},{"orgOrder":0,"company":"OncoQuest","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Carboplatin","moa":"||Mucin-16","graph1":"Oncology","graph2":"Phase III","graph3":"OncoQuest","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"OncoQuest \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"OncoQuest \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by OncoQuest

    Menu

    OncoQuest

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            OncoQuest

                            Canada arrow
                            Global ChemShow
                            Not Confirmed

                            OncoQuest

                            Canada arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Dual Industrial

                            Deal Size : $375 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Dual Industrial to Buy OncoQuest's immunotherapy Drug Portfolio and Commit to fund Oregovomab Phase 3 Clinical...

                            Details : Agreement includes Quest PharmaTech's clinical and preclinical immunotherapy development assets. Dual Industrial will also fund OncoQuest's Phase 3 trial for oregovomab in frontline ovarian cancer.

                            Product Name : OvaRex

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            April 22, 2020

                            Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Dual Industrial

                            Deal Size : $375 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            OncoQuest

                            Canada arrow
                            Global ChemShow
                            Not Confirmed

                            OncoQuest

                            Canada arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            OncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Trial

                            Details : First study data shows that orgeovomab did not add incremental toxicity to chemotherapy. Second study offers development of a readily accessible prognostic indicator for orgeovomab chemoimmunotherapy.

                            Product Name : OvaRex

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 24, 2020

                            Lead Product(s) : Oregovomab,Carboplatin,Paclitaxel

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth